Bloodborne Pathogens Standard: Research Labs

Almost everything written about OSHA’s Bloodborne Pathogens Standard is written for a hospital. It explains Universal Precautions, the exposure control plan, sharps containers, the hepatitis B vaccination offer and the post-exposure workup — and then stops. That guidance is not wrong, but it covers roughly paragraphs (c) through (h) of a standard that also contains a paragraph (e) aimed squarely at research laboratories and production facilities, and it never mentions it.

Paragraph (e) is a different animal. It is a containment standard, not an infection-control standard. It requires certified biological safety cabinets, an available autoclave, a separate written biosafety manual, directional airflow in production settings, and a training gate that an employee must pass before being allowed to work with the agent at all. None of that appears in clinical bloodborne pathogens training.

Two questions decide whether any of it reaches your laboratory, and they are not the same question:

Are you in scope of 29 CFR 1910.1030 at all? That turns on whether employees have reasonably anticipated contact with human blood or other potentially infectious materials (OPIM) — and this is where human cell lines and tissue cultures catch out basic-science labs that have never drawn a tube of blood.
Are you additionally in scope of paragraph (e)? That is a much narrower test, and it is about what you do with HIV and HBV, not about what you handle generally.

This page answers both, clause by clause from the regulation, and sets out OSHA’s actual documented position on cell lines — which is more nuanced, and in one direction stricter, than the version that circulates in lab-safety folklore.

The three-tier scope model

It helps to stop thinking of 1910.1030 as one on/off switch. In a research institution there are three distinct positions a laboratory can occupy:

Tier	What it means	What applies
Out of scope	No reasonably anticipated employee contact with human blood or OPIM. A synthetic-chemistry lab, a plant-science lab, a lab working only with documented pathogen-free established cell lines.	Nothing in 1910.1030. Other standards (the Laboratory Standard, HazCom) still apply on their own terms.
General scope	Occupational exposure to blood or OPIM exists — primary human tissue, unfixed human specimens, human body fluids, primary cell cultures.	Paragraphs (c) exposure control plan, (d) methods of compliance including Universal Precautions, (f) hepatitis B vaccination and post-exposure follow-up, (g) hazard communication and training, (h) recordkeeping.
Paragraph (e) scope	The laboratory cultures, produces, concentrates, experiments with, or manipulates HIV or HBV specifically.	Everything in general scope, plus the containment, practice, facility and training requirements of (e). These are additive, never a substitute.

The single most common misreading is to treat tier three as a synonym for “we work at BSL-2 with human material.” It is not. A BSL-2 lab handling primary human tissue sits firmly in tier two and owes nothing under (e). A lab that propagates HIV in culture sits in tier three even if its volumes are small.

What triggers paragraph (e), exactly

The scoping sentence is 29 CFR 1910.1030(e)(1), and it is worth reading in full rather than paraphrased:

“This paragraph applies to research laboratories and production facilities engaged in the culture, production, concentration, experimentation, and manipulation of HIV and HBV. It does not apply to clinical or diagnostic laboratories engaged solely in the analysis of blood, tissues, or organs. These requirements apply in addition to the other requirements of the standard.”

Three things follow from that text and are worth stating plainly:

The named agents are HIV and HBV, and only those. Paragraph (e) does not reach hepatitis C, HTLV, or any other bloodborne agent, however serious. HCV is treated identically to HBV and HIV in the general parts of the standard through the OPIM definition and Universal Precautions, but it does not pull a laboratory into (e). If your containment case rests on HCV, it rests on the BMBL biosafety level framework and your Institutional Biosafety Committee, not on this paragraph.
The verbs are broad. “Culture, production, concentration, experimentation, and manipulation” is not limited to producing high-titre stocks. Experimental manipulation of HIV or HBV — infection assays, transduction with HBV constructs that generate replication-competent virus, propagation of an infectious clone — is manipulation.
The carve-out is narrow and conditional on the word “solely.” A clinical or diagnostic laboratory that only analyses specimens is excluded. A hospital laboratory with an attached research arm that cultures HIV is not excluded for that work merely because the rest of the building is diagnostic.

Research laboratory vs. production facility — the definitions do the work

Paragraph (e) splits into two sets of facility criteria, and which one applies to you is decided by two definitions in paragraph (b):

	Research Laboratory — 1910.1030(b)	Production Facility — 1910.1030(b)
Regulatory definition	“a laboratory producing or using research-laboratory-scale amounts of HIV or HBV. Research laboratories may produce high concentrations of HIV or HBV but not in the volume found in production facilities.”	“a facility engaged in industrial-scale, large-volume or high concentration production of HIV or HBV.”
The distinguishing axis	Volume, not concentration. A university lab can run genuinely high-titre preparations and still be a research laboratory.	Industrial scale and large volume — vaccine or diagnostic-reagent manufacture, not a bench-scale prep.
Which criteria apply	(e)(2) plus (e)(3)	(e)(2) plus (e)(4)

This matters because the (e)(4) production-facility criteria are architectural — two sets of doors, sealed surfaces, ducted single-pass exhaust — and cannot be retrofitted with a procurement order. Institutions occasionally read (e) as a single block and conclude they need an airlock for a two-litre virus prep. They do not. Read (e)(3) and (e)(4) as alternatives selected by the definitions above.

(e)(2): the practices and containment every (e) facility owes

Paragraph (e)(2) applies to research laboratories and production facilities alike. It has three sub-parts.

(e)(2)(i) Standard microbiological practices

One requirement, and it is absolute: all regulated waste must be either incinerated or decontaminated by a method such as autoclaving known to effectively destroy bloodborne pathogens. Note there is no chemical-disinfection-and-landfill option written into this clause for (e) facilities the way institutions sometimes operate for general regulated waste. If your waste stream routing relies on a treatment vendor downstream, the treatment still has to happen; see also the question of whether autoclaved regulated waste remains regulated under state rules.

(e)(2)(ii) Special practices — the thirteen clauses, (A) through (M)

These are the provisions that most distinguish an (e) laboratory from an ordinary BSL-2 lab operating under Universal Precautions. Several of them are routinely missed:

Clause	Requirement	What it means in practice
(A)	Laboratory doors kept closed when work involving HIV or HBV is in progress.	A door-open-for-airflow habit is a citable practice failure, not a preference.
(B)	Contaminated material for off-site decontamination goes in a durable, leakproof, labelled or colour-coded container, closed before leaving the work area.	Closed before removal — not closed at the autoclave.
(C)	Access limited to authorised persons, under written policies and procedures: entrants must have been advised of the biohazard, meet entry requirements, and comply with entry and exit procedures.	This is a documented access-control procedure, not a locked door. It is one of the two written artefacts (e) demands.
(D)	Biohazard warning sign on all access doors when OPIM or infected animals are present, complying with (g)(1)(ii).	Sign content is governed by the labels-and-signs paragraph, including the required legend elements.
(E)	All activities involving OPIM conducted in biological safety cabinets or other physical-containment devices within the containment module. No work with OPIM on the open bench.	The hardest clause in (e). It is not risk-assessed by aerosol potential the way BSL-2 practice is — under (e) it is categorical.
(F)	Protective clothing used in work area and animal rooms, not worn outside the work area, decontaminated before laundering.	Decontaminate before laundering, which rules out a routine soiled-linen route. See PPE removal sequencing.
(G)	Special care to avoid skin contact; gloves worn when handling infected animals and when hand contact with OPIM is unavoidable.	—
(H)	All waste from work areas and animal rooms incinerated or decontaminated before disposal.	All waste, not only regulated waste — broader than (e)(2)(i).
(I)	Vacuum lines protected with liquid disinfectant traps and HEPA filters (or equivalent), checked routinely and maintained or replaced as necessary.	Both, not either. A flask of bleach alone does not satisfy this, and the filter needs a documented check interval.
(J)	Hypodermic needles and syringes only for parenteral injection and aspiration from laboratory animals and diaphragm bottles. Only needle-locking syringes or integral syringe-needle units for OPIM. No bending, shearing, resheathing, or removal from the syringe. Prompt placement in a puncture-resistant container, autoclaved or decontaminated before reuse or disposal.	Luer-slip syringes are effectively prohibited for this work. See the first-hour needlestick protocol for what happens when this fails.
(K)	All spills immediately contained and cleaned up by appropriate professional staff or others properly trained and equipped to work with potentially concentrated infectious materials.	Not “whoever spilled it.” A named, trained, equipped responder.
(L)	A spill or accident resulting in an exposure incident immediately reported to the laboratory director or other responsible person.	Reporting line runs to the laboratory director, in addition to the (f)(3) post-exposure medical pathway.
(M)	A biosafety manual prepared or adopted, and periodically reviewed and updated at least annually. Personnel advised of potential hazards, required to read instructions on practices and procedures, and required to follow them.	The second written artefact. Separate from the exposure control plan, and with its own annual review clock.

(e)(2)(iii) Containment equipment

Two clauses, both frequently cited:

(e)(2)(iii)(A) — certified biological safety cabinets (Class I, II, or III) or other appropriate combinations of personal protection or physical containment devices, such as special protective clothing, respirators, centrifuge safety cups, sealed centrifuge rotors, and containment caging for animals, for all activities with OPIM that pose a threat of exposure to droplets, splashes, spills or aerosols. The regulation explicitly names sealed rotors and safety cups, so a centrifuge protocol is part of your (e) compliance case, not an afterthought.
(e)(2)(iii)(B) — biological safety cabinets shall be certified when installed, whenever they are moved, and at least annually. Three triggers. The “whenever moved” trigger is the one that gets missed during lab relocations and bench reconfigurations. What that certification involves is set out in NSF/ANSI 49 field testing.

(e)(3) and (e)(4): the facility criteria that diverge

Requirement	Research laboratory — (e)(3)	Production facility — (e)(4)
Handwashing	A facility for hand washing within the laboratory.	A sink in each work area, foot, elbow or automatically operated, located near the exit door.
Eyewash	An eyewash facility readily available within the work area.	A readily available eyewash facility in each work area.
Autoclave	An autoclave for decontamination of regulated waste shall be available.	An autoclave within or as near as possible to the work area.
Entry separation	Not required.	Work areas separated from unrestricted traffic flow; passage through two sets of doors is the basic requirement, or a double-doored change room (showers may be included), airlock, or equivalent.
Surfaces	Not required.	Doors, walls, floors and ceilings water resistant and easily cleaned; penetrations sealed or capable of being sealed to facilitate decontamination.
Doors	Not required.	Access doors to the work area or containment module self-closing.
Ventilation	Not required.	A ducted exhaust-air ventilation system creating directional airflow drawing air in through the entry area; exhaust not recirculated to any other area, discharged outside and dispersed away from occupied areas and air intakes; airflow direction verified.

Note the wording on the research-laboratory autoclave. The requirement is that one be available, not that one be inside the room. A shared autoclave on the same floor, reachable without carrying open waste through uncontrolled space and consistent with the (e)(2)(ii)(B) closed-container rule, satisfies (e)(3)(ii). The production-facility clause is the one that adds proximity.

Note also what (e) does not require of a research laboratory: no anteroom, no directional airflow, no sealed surfaces, no self-closing doors. Those are BSL-3 design features under the BMBL, and a research laboratory can meet every clause of (e) in a well-equipped BSL-2 facility. If your institution has been told it needs BSL-3 construction to hold an (e) laboratory, that requirement is coming from a risk assessment or a funder condition, not from 1910.1030.

(e)(5): the training criteria are a gate, not a module

Paragraph (e)(5) is a single cross-reference — additional training requirements are specified at (g)(2)(ix) — and it is the most under-implemented part of the whole paragraph. Institutions satisfy it by adding a slide deck. The text requires something structurally different: three eligibility conditions that precede the work.

Clause	Requirement	Why it is not a training module
(g)(2)(ix)(A)	Employees must demonstrate proficiency in standard microbiological practices and techniques, and in the practices and operations specific to the facility, before being allowed to work with HIV or HBV.	Demonstrated proficiency, assessed by someone, recorded. A post-test score is not a demonstration of technique.
(g)(2)(ix)(B)	Employees must have prior experience in the handling of human pathogens or tissue cultures before working with HIV or HBV.	An experience prerequisite. A first-year graduate student with no prior culture experience is not eligible on day one, however good the training.
(g)(2)(ix)(C)	For employees with no prior experience handling human pathogens, the employer must provide a training programme in which initial work activities do not include the handling of infectious agents, work is assigned as a progression as techniques are learned, and participation in work involving infectious agents happens only after proficiency has been demonstrated.	A staged onboarding with a documented progression — mock work first, agent work later. This is a supervision plan, not a course.

The practical consequence: an (e) laboratory needs a per-person record showing prior experience or a completed progression, and a proficiency sign-off dated before first agent access. That record sits alongside, not inside, the annual bloodborne pathogens training documented under (g)(2) — the general annual requirement is covered in detail on our bloodborne pathogens training page.

The human cell line question — where basic-science labs get pulled in

This is the part that catches laboratories that have never touched a blood tube, and it operates at tier two, not tier three. It is a question about OPIM, not about paragraph (e).

What the regulation actually says

The OPIM definition at 1910.1030(b) has three limbs. The relevant ones here are:

(2) — “Any unfixed tissue or organ (other than intact skin) from a human (living or dead).”
(3) — “HIV-containing cell or tissue cultures, organ cultures, and HIV- or HBV-containing culture medium or other solutions; and blood, organs, or other tissues from experimental animals infected with HIV or HBV.”

Read literally, limb (3) covers only cultures containing HIV or HBV. An immortalised human cell line of unknown viral status is not named anywhere in the definition. That textual gap is why the question was referred to OSHA in the first place, and it is why the answer lives in an interpretation letter rather than in the rule.

OSHA’s documented position

OSHA’s operative statement is a letter of interpretation dated 21 June 1994, addressed to Dr Diane Fleming and issued by the Director of the Office of Health Compliance Assistance. It replaced an earlier 3 August 1993 letter to the American Biological Safety Association that OSHA itself acknowledged had caused confusion. The 1994 letter draws a line that is finer than the version usually repeated:

Material	OSHA’s stated position	Covered by 1910.1030?
Established human cell lines (immortalised/transformed), characterised to be free of contamination from human hepatitis viruses, HIV and other recognised bloodborne pathogens	“are not considered to be OPIM and are not covered by BPS”	No, if characterised and documented
Established human or other animal cell lines known to be, or likely to be, infected or contaminated with agents classed as bloodborne pathogens	Covered	Yes
All primary human cell explants from tissues, and subsequent in vitro passages of human tissue explant cultures (human cell “strains”)	“must be regarded as containing potential bloodborne pathogens and should be handled in accordance with the BPS”	Yes by default — exemptible only by documented testing
Non-transformed human cell strains characterised by documented, reasonable laboratory testing to be free of HIV, hepatitis viruses or other bloodborne pathogens	“may be exempted from the standard’s requirements”	No, if documented
Explants or cultures derived from human subjects known to carry bloodborne pathogens, or deliberately infected	Must be handled under the standard regardless of passage	Yes
Animal tissues, explants or cell cultures deliberately infected with HIV or HBV	Subject to the standard	Yes
All laboratory work with primary human tissues or body fluids	“is covered by the BPS” — stated without qualification	Yes

Two corrections follow, and they point in opposite directions:

Against the strict folk version — it is not true that every human cell line is OPIM. A documented, characterised, protected established line is outside the standard on OSHA’s own statement, and a lab running only such lines is in tier one.
Against the lax folk version — the exemption is not self-executing and does not extend to primary material. Primary explants and their passages are covered by default. The burden runs the other way: the material is OPIM until characterisation says otherwise.

The documentation OSHA expects

The letter is specific about who decides and what survives the decision:

The final judgement that cells in culture are free of bloodborne pathogens must be made by a biosafety professional or other qualified scientist with the background and experience to review the potential contamination and risk. Not by the principal investigator by default, and not by a purchasing note.
“Documentation that such cell lines are not OPIM should be a matter of written record and on file with the employer for OSHA review.” A vendor certificate in a drawer in the lab is not a record on file with the employer.
Cell lines procured from commercial vendors with documented testing to be free of human bloodborne pathogens and which have been protected by the employer from environmental contamination may be excluded. Both halves matter: the provenance document and the ongoing protection from cross-contamination in your own facility.

The attachment to the letter also does two things worth knowing. It defines a human cell line as an immortalised culture transformed by spontaneous mutation or by natural or laboratory infection with an immortalising agent such as Epstein-Barr virus — and states flatly that EBV is a bloodborne pathogen, which is why EBV-transformed lymphoblastoid lines cannot be waved through as “just a cell line”. And it defines a human cell strain as cells propagated from primary explants with a finite lifetime of roughly 20 to 70 passages, naming WI-38 as an example of a strain that is often documented.

It also names HeLa directly: to handle HeLa without complying with the standard, the cells “should be documented to be pure HeLa cells and shown to be free of bloodborne pathogens by testing” — because transformed lines are, in OSHA’s words, sometimes adulterated by laboratory pathogens accidentally introduced through cultivation alongside other cultures. The characterisation methods the attachment contemplates include antigenic screening for viral markers, co-cultivation with indicator cells, and molecular detection by PCR or nucleic acid hybridisation for latent viruses. That overlaps with, but is not satisfied by, routine mycoplasma testing — mycoplasma is not a bloodborne pathogen and clearing it proves nothing about HIV, HBV or EBV.

A caution on status: this is a letter of interpretation, and OSHA’s own standing preamble on interpretation letters states that they explain requirements and how they apply to particular circumstances but cannot create additional employer obligations, and that enforcement guidance may be affected by changes to OSHA rules. It is the best available statement of OSHA’s position on a question the rule text does not resolve — not a regulatory provision. Cite it as such.

A decision rule you can put in a biosafety manual

Is the material primary human tissue, a primary explant, a passage of one, or any human body fluid? Treat as OPIM. Tier two applies unless a qualified biosafety professional has documented characterisation testing.
Is it an established, immortalised line with vendor or in-house documentation of testing for HIV, hepatitis viruses and EBV, held under conditions protecting it from cross-contamination? Not OPIM, provided that documentation is on file with the employer, not only in the lab.
Is it an established line with no such documentation, or with a known or likely bloodborne-pathogen contamination? Treat as OPIM.
Is HIV or HBV being cultured, produced, concentrated, experimented with or manipulated in the space? Paragraph (e) applies on top, and (e)(2)(ii)(E) removes the open bench as an option.

Nothing in step 4 changes the answer to steps 1 to 3, and nothing in steps 1 to 3 answers step 4. They are independent tests.

Cross-walk: which standard owns which obligation

Research laboratories sit under several overlapping OSHA standards, and the boundary rules are not intuitive. This extends the same logic set out for chemicals on our Hazard Communication Standard in the research laboratory and written HazCom program pages.

Instrument	What it governs	Relationship to 1910.1030
29 CFR 1910.1030	Occupational exposure to human blood and OPIM; biological hazard from bloodborne agents.	The instrument on this page. Applies on its own terms, independently of every item below.
29 CFR 1910.1450 (Laboratory Standard)	Occupational exposure to hazardous chemicals in laboratories; requires a Chemical Hygiene Plan.	No overlap of subject matter. A CHP is not a biosafety manual and cannot satisfy (e)(2)(ii)(M); the biosafety manual cannot satisfy the CHP.
29 CFR 1910.1200 (HazCom)	Chemical hazard classification, labels, SDSs and a written program — largely displaced inside laboratories by 1910.1450.	Unrelated subject matter, but the (g)(1) labels and signs requirements of 1910.1030 are the biohazard analogue and are separately enforceable.
BMBL and the NIH Guidelines	Biosafety levels, risk-group assignment, recombinant and synthetic nucleic acid oversight, IBC review.	Guidance and funding conditions, not OSHA rules. A lab can be fully BMBL-compliant at BSL-2 and still be cited under 1910.1030. Conversely, (e) compliance does not discharge IBC obligations.

The practical version: your biosafety officer owns the BMBL and NIH Guidelines side, your EHS office owns the OSHA side, and paragraph (e) is the clause where the two most often need to be reconciled in one document set — because the biosafety manual (e)(2)(ii)(M) requires is usually the institution’s BMBL-shaped manual, which then has to be checked clause by clause against (e) rather than assumed to cover it.

What a compliance officer asks for in an (e) laboratory

If an inspection reaches a laboratory in paragraph (e) scope, the document set requested is predictable, because each item maps to a clause:

The exposure control plan, reviewed and updated within the last twelve months, with the exposure determination by job classification and by task — (c)(1) and (c)(2).
The biosafety manual, as a separate document, with evidence of review within the last twelve months and a record that personnel have read it — (e)(2)(ii)(M).
The written access policy: who is authorised, how they were advised of the biohazard, and the entry and exit procedures — (e)(2)(ii)(C).
Biological safety cabinet certification records showing certification at installation, after any move, and within the last twelve months — (e)(2)(iii)(B).
Vacuum line protection: evidence of both disinfectant traps and HEPA or equivalent filters, plus the routine check record — (e)(2)(ii)(I).
Per-employee eligibility records: prior experience with human pathogens or tissue cultures, or a documented progression programme, plus a dated proficiency demonstration preceding first agent access — (g)(2)(ix)(A) to (C).
Hepatitis B vaccination records or signed Appendix A declination statements, and the training that preceded the offer — (f)(2) and (g)(2)(vii)(I).
Cell line characterisation documentation for any material the laboratory treats as outside the standard, on file with the employer — per the 1994 interpretation.
Waste treatment evidence — incineration or validated decontamination for all work-area and animal-room waste, not only for regulated waste — (e)(2)(i) and (e)(2)(ii)(H).

Broader laboratory-wide practice expectations that sit outside (e) but are routinely examined in the same visit are covered on our laboratory safety rules and BSL-2 facility requirements pages.

Frequently asked questions

Does the Bloodborne Pathogens Standard apply to a research laboratory?

Yes, wherever employees have reasonably anticipated skin, eye, mucous membrane or parenteral contact with human blood or OPIM. That includes work with primary human tissue, unfixed human specimens, human body fluids and primary cell cultures — no patient contact and no phlebotomy is required. Paragraph (e) applies additionally, and only, where the laboratory cultures, produces, concentrates, experiments with or manipulates HIV or HBV.

What is 29 CFR 1910.1030 paragraph (e)?

It is the section of the Bloodborne Pathogens Standard titled “HIV and HBV Research Laboratories and Production Facilities.” It adds containment and practice requirements — biological safety cabinets certified at installation, on relocation and annually; no open-bench work with OPIM; protected vacuum lines; a separate biosafety manual reviewed at least annually; written access-control procedures; a demonstrated-proficiency training gate — on top of the requirements that apply to every covered employer. It expressly does not apply to clinical or diagnostic laboratories engaged solely in analysing blood, tissues or organs.

Are human cell lines covered by the Bloodborne Pathogens Standard?

It depends on the material, and OSHA’s position comes from a letter of interpretation dated 21 June 1994 rather than from the rule text. Established, immortalised human cell lines that have been characterised to be free of hepatitis viruses, HIV and other recognised bloodborne pathogens are not OPIM and are not covered. All primary human cell explants and their subsequent passages must be regarded as potentially containing bloodborne pathogens and are covered unless documented testing establishes otherwise. All laboratory work with primary human tissues or body fluids is covered. The determination must be made by a biosafety professional or other qualified scientist and kept as a written record on file with the employer.

Is HeLa covered by the Bloodborne Pathogens Standard?

Not automatically in either direction. The attachment to OSHA’s 1994 interpretation names HeLa specifically and states that to handle it outside the standard, the cells should be documented to be pure HeLa and shown by testing to be free of bloodborne pathogens — because transformed lines can be adulterated by pathogens introduced through cultivation alongside other cultures. An undocumented HeLa stock of uncertain provenance does not meet the exemption.

Does a research laboratory covered by paragraph (e) need to be BSL-3?

No. Paragraph (e)(3) requires only a handwashing facility, a readily available eyewash within the work area, and an available autoclave, on top of the (e)(2) practices and containment equipment. Anterooms, directional airflow, sealed surfaces and self-closing doors appear in (e)(4), which applies to production facilities engaged in industrial-scale or large-volume production. A BSL-3 requirement for a given agent comes from the BMBL risk assessment or a funder condition, not from 1910.1030.

Does a Chemical Hygiene Plan satisfy the biosafety manual requirement?

No. The Chemical Hygiene Plan is required by the Laboratory Standard, 29 CFR 1910.1450, and addresses hazardous chemicals. The biosafety manual required by 1910.1030(e)(2)(ii)(M) addresses bloodborne pathogen practices and procedures and carries its own at-least-annual review obligation. They are different documents under different standards, and neither substitutes for the other — nor for the exposure control plan, which is a third document under (c)(1).

Does paragraph (e) apply to hepatitis C work?

No. Paragraph (e)(1) names HIV and HBV only. HCV is treated as a bloodborne pathogen for the purposes of the general standard — Universal Precautions, the exposure control plan, PPE, post-exposure follow-up — but culturing or concentrating HCV does not by itself trigger the (e) containment criteria. Containment expectations for HCV work derive from the BMBL and your Institutional Biosafety Committee.

How often must the biosafety manual be reviewed?

At least annually, and more often if necessary, under 1910.1030(e)(2)(ii)(M). That is a separate clock from the exposure control plan’s annual review under (c)(1)(iv) and from the annual training requirement under (g)(2)(ii)(B). Institutions often align all three to one date; the standard does not require that, but it makes the records legible to an inspector.

Do biological safety cabinets have to be recertified when moved?

Yes. Paragraph (e)(2)(iii)(B) requires certification when installed, whenever the cabinet is moved, and at least annually. The relocation trigger is independent of the annual one — moving a cabinet in month three does not reset or replace the annual certification due in month twelve.